1403-66-3|庆大霉素|Gentamicin|MFCD00072030-范德生物科技公司

庆大霉素
NMR and HPLC COA下载 MSDS下载
Names：
Gentamicin
CAS号：
1403-66-3
MDL Number： MFCD00072030
MF(分子式)： C60H123N15O21 MW(分子量)： 477.6g/mol
EINECS:215-765-8 Reaxys Number:
Pubchem ID:3467 Brand:BIOFOUNT

庆大霉素(Gentamicin,1403-66-3)是一种广谱氨基糖苷类抗生素，是通过发酵小单孢菌或棘孢棘孢菌产生的。庆大霉素是一种抗生素复合物，由四个主要成分（C1，C1a，C2和C2a）和几个次要成分组成。该试剂不可逆地与细菌30S核糖体亚基结合。具体而言，该抗生素位于30S亚基内的16S rRNA和S12蛋白之间。这导致对翻译起始复合物的干扰，mRNA的误读，从而阻碍了蛋白质的合成并导致了杀菌作用。氨基糖苷对厌氧细菌，真菌和病毒大多无效。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
SS0338-50mg	50mg	对照品	¥ 1250.00	¥ 1250.00		3-5days	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	庆大霉素(1403-66-3),正泰霉素,艮他霉素
英文别名	Gentamicin(1403-66-3),gentamicin, Garamycin, Gentavet, Gentamicins, Gentamycinum, Cidomycin, Garasol
CAS号	1403-66-3
SMILES	CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC
Inchi	InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3/t9?,10-,11+,12-,13+,14+,15-,16-,17+,18-,19-,20-,21+/m1/s1
InchiKey	CEAZRRDELHUEMR-URQXQFDESA-N
分子式 Formula	C60H123N15O21
分子量 Molecular Weight	477.6g/mol
闪点 FP	358.6±31.5 °C
熔点 Melting point	105 °C
沸点 Boiling point	669.4±55.0 °C at 760 mmHg
Polarizability极化度	48.6±0.5 10-24cm3
密度 Density	1.3±0.1 g/cm3
蒸汽压 Vapor Pressure	0.0±4.6 mmHg at 25°C
溶解度Solubility	100 mg/mL
性状	Solid
储藏条件 Storage conditions	4°C条件下存储,-4摄氏度存储更佳

庆大霉素(Gentamicin,1403-66-3)毒理性质：

动物	测试类型	途径	实验摄入量 (标准摄入量)	影响	文献来源
cat	LD50	intramuscular	430mg/kg (430mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: ATAXIA	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 11, 1966.
cat	LD50	intraperitoneal	304mg/kg (304mg/kg)	LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: ATAXIA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 11, 1966.
cat	LD50	intravenous	88mg/kg (88mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: ATAXIA	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 11, 1966.
dog	LD50	intramuscular	750mg/kg (750mg/kg)	LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: ATAXIA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 11, 1966.
dog	LD50	intraperitoneal	710mg/kg (710mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 11, 1966.
dog	LD50	intravenous	184mg/kg (184mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 11, 1966.
guinea pig	LD50	intraperitoneal	530mg/kg (530mg/kg)	LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: ATAXIA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 11, 1966.
guinea pig	LD50	subcutaneous	740mg/kg (740mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 11, 1966.
human	TDLo	intravenous	2mg/kg (2mg/kg)	KIDNEY, URETER, AND BLADDER: OTHER CHANGES	New England Journal of Medicine. Vol. 303, Pg. 1002, 1980.
human	TDLo	intravenous	23mg/kg/1Y-I (23mg/kg)	PERIPHERAL NERVE AND SENSATION: SENSORY CHANGE INVOLVING TRIGEMINAL NERVE	Archives of Internal Medicine. Vol. 138, Pg. 1621, 1978.
infant	TDLo	intramuscular	20mg/kg (20mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	Pediatrics. Vol. 77, Pg. 848, 1986.
man	TDLo	intramuscular	8mg/kg/2W-I (8mg/kg)	SENSE ORGANS AND SPECIAL SENSES: HEMORRHAGE: EYE SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE SKIN AND APPENDAGES (SKIN): HAIR: OTHER	JAMA, Journal of the American Medical Association. Vol. 211, Pg. 123, 1970.
mouse	LD50	intramuscular	167mg/kg (167mg/kg)	BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)	Japanese Journal of Antibiotics. Vol. 35, Pg. 461, 1982.
mouse	LD50	intraperitoneal	235mg/kg (235mg/kg)		Journal of International Medical Research. Vol. 2, Pg. 100, 1974.
mouse	LD50	intravenous	43500ug/kg (43.5mg/kg)		Antibiotiki. Vol. 21, Pg. 532, 1976.
mouse	LD50	oral	10gm/kg (10000mg/kg)	BEHAVIORAL: ATAXIA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)	Japanese Journal of Antibiotics. Vol. 30, Pg. 386, 1977.
mouse	LD50	subcutaneous	274mg/kg (274mg/kg)		Toxicology and Applied Pharmacology. Vol. 25, Pg. 398, 1973.
rabbit	LD50	intramuscular	780mg/kg (780mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 11, 1966.
rabbit	LD50	intraperitoneal	1350mg/kg (1350mg/kg)	LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: ATAXIA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 11, 1966.
rabbit	LD50	intravenous	81mg/kg (81mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 11, 1966.
rabbit	LD50	subcutaneous	1230mg/kg (1230mg/kg)	BEHAVIORAL: ATAXIA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 11, 1966.
rat	LD50	intramuscular	463mg/kg (463mg/kg)		Japanese Journal of Antibiotics. Vol. 35, Pg. 461, 1982.
rat	LD50	intraperitoneal	735mg/kg (735mg/kg)		Journal of International Medical Research. Vol. 2, Pg. 100, 1974.
rat	LD50	intravenous	70mg/kg (70mg/kg)		Journal of International Medical Research. Vol. 2, Pg. 100, 1974.
rat	LD50	oral	6600mg/kg (6600mg/kg)	BEHAVIORAL: TREMOR GASTROINTESTINAL: OTHER CHANGES BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Archives des Maladies Professionnelles de Medecine du Travail et de Securite Sociale. Vol. 39, Pg. 259, 1978.
rat	LD50	subcutaneous	710mg/kg (710mg/kg)		Journal of International Medical Research. Vol. 2, Pg. 100, 1974.
women	TDLo	intravenous	8200ug/kg/12D (8.2mg/kg)	SENSE ORGANS AND SPECIAL SENSES: CHANGES IN VESTIBULAR FUNCTIONS: EAR BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"	Acta Pathologica et Microbiologica Scandinavica, Section B: Microbiology and Immunology. Vol. 81(Suppl,

庆大霉素(Gentamicin,1403-66-3)物理性质：

Physical Property	Value	Units	Temp (deg C)	Source
Melting Point	105	deg C		EXP
log P (octanol-water)	-1.880	(none)		EST
Atmospheric OH Rate Constant	4.05E-10	cm3/molecule-sec	25	EST

庆大霉素C1a,对照品(1403-66-3)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。
5.取药品时尽量采用多个药勺分别使用，使用后清洗干净后，烘干消毒存放。
6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:庆大霉素蒸汽压,庆大霉素合成,庆大霉素标准,庆大霉素应用,庆大霉素合成,庆大霉素沸点,庆大霉素闪点,庆大霉素用途,庆大霉素溶解度,庆大霉素价格,庆大霉素作用,庆大霉素结构式,庆大霉素用处

产品说明	庆大霉素(1403-66-3)是一种广谱氨基糖苷类抗生素,是通过发酵小单孢菌或棘孢棘孢菌产生的.庆大霉素应用,庆大霉素MSDS,庆大霉素1403-66-3其他参数见主页
Introduction	Gentamicin:(庆大霉素,1403-66-3) used for scientific research and chemical synthesis intermediates
Application1
Application2
Application3

1.Gentamicin is a broad-spectrum aminoglycoside antibiotic produced by fermentation of Micromonospora purpurea or M. echinospora. Gentamicin is an antibiotic complex consisting of four major (C1, C1a, C2, and C2a) and several minor components. This agent irreversibly binds to the bacterial 30S ribosomal subunit. Specifically, this antibiotic is lodged between 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex, misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.
2.Gentamicin is a parenterally administered, broad spectrum aminoglycoside antibiotic typically used for moderate to severe gram negative infections. Despite its wide use, gentamicin has not been definitively linked to instances of clinically apparent liver injury.
3.A complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1a, obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (genetic translation).

警示图
危险性	Danger
危险性警示	No data available
安全声明	H317 (55.42%) H334 (55.42%) H360 (44.58%)
安全防护	P264+P280+P305+P351+P338+P337+P313
备注	实验过程中防止吸入、食入，做好安全防护

H317 (55.42%): May cause an allergic skin reaction [Warning Sensitization, Skin] H334 (55.42%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] H360 (44.58%): May damage fertility or the unborn child [Danger Reproductive toxicity] H372 (44.58%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] H400 (44.58%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard] H410 (44.58%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.

George H. Scherr, "Preparation of gentamicin sensitized particles for agglutination tests." U.S. Patent US4100268, issued August, 1975.

Injectable Amoxicillin Versus Injectable Ampicillin Plus Gentamicin in the Treatment of Severe Pneumonia in Children Aged 2 to 59 Months: Protocol for an Open-Label Randomized Controlled Trial PMID 33

Feasibility and efficacy of gentamicin for treating neonatal sepsis in community-based settings: a systematic review PMID 26830306; World journal of pediatrics : WJP 2016 Nov; 12(4):408-414 (Review Ar

3,923 articles Download CSVView in PubMed Injectable Amoxicillin Versus Injectable Ampicillin Plus Gentamicin in the Treatment of Severe Pneumonia in Children Aged 2 to 59 Months: Protocol for an Op

Adsorption of vancomycin, gentamycin, ciprofloxacin and tygecycline on the filters in continuous renal replacement therapy circuits: in full blood in vitro study PMID 33033945; Journal of artificial o

1.Bacteriophage-antibiotic combinations against ciprofloxacin/ceftriaxone-resistant Escherichia coli in vitro and in an experimental Galleria mellonella model/PMID 33075514; International journal of antimicrobial agents 2020 Oct; ?(?):106200/Name matches: ciprofloxacin gentamicin
Abstract:Escherichia coli is the most common cause of Gram-negative prosthetic joint infections (PJIs) and ciprofloxacin is the first-line antibiofilm antibiotic. Due to the emergence of fluoroquinolone resistance, management of E. coli PJIs has become challenging and is associated with high treatment failure rates. We evaluated the efficacy of a newly isolated bacteriophage ?WL-3 as a therapeutic agent in combination with ciprofloxacin, fosfomycin, gentamicin, meropenem or ceftriaxone against biofilm of a ciprofloxacin/ceftriaxone-resistant E. coli strain and the ATCC 25922 reference strain. ?WL-3 was first characterised in terms of virion morphology, absorption rate, burst size and killing kinetics against both E. coli strains. The tested antibiotics presented high inhibitory concentrations (ranging from 16 to >1024 μg/mL) when tested alone against biofilms. Co-administration of ?WL-3 with antibiotics improved the antibiotic efficacy against biofilm, especially after staggered exposure, reducing the minimum biofilm bactericidal concentration (MBBC) up to 512 times. The in vivo antimicrobial activity of ?WL-3/fosfomycin combination against both E. coli strains was assessed in a Galleria mellonella invertebrate infection model. Treatment of infected larvae after lethal doses of E. coli resulted in enhanced survival rates when combinatorial therapy with ?WL-3/fosfomycin was applied on E. coli ATCC 25922-infected larvae compared with monotherapy, but not for EC1-infected larvae, which we speculated could be due to higher release of endotoxins in a shorter period in EC1-infected larvae exposed to ?WL-3. Our study provides new insights into the use of bacteriophages and antibiotics in the treatment of biofilm-associated infections caused by antibiotic-resistant bacteria.

2.Effect of Ceftaroline, Vancomycin, Gentamicin, Macrolides, and Ciprofloxacin against Methicillin-Resistant Staphylococcus aureus Isolates: An In Vitro Study/PMID 31513456; Surgical infections 2020 Mar; 21(2):150-157/Name matches: ciprofloxacin gentamicin
Abstract:Background: Methicillin-resistant Staphylococcus aureus (MRSA) infection remains a challenging threat because of limited treatment options. Ceftaroline was identified as having potent anti-MRSA activity. Aim: To evaluate the susceptibility of MRSA to gentamicin, macrolides, ciprofloxacin, vancomycin, and ceftaroline and to perform molecular characterization of different resistance genes as aminoglycoside modifying enzyme genes, ermA and ermC, and vanA and vanB genes. Patients and Methods: One hundred non-duplicate MRSA strains were isolated from different samples of hospitalized patients in Cairo University teaching hospitals from November 2015 to August 2016. Determination of antibiotic susceptibility was done using disk diffusion test and minimum inhibitory concentration followed by detection of resistance genes by multiplex polymerase chain reaction (PCR). Results: Of 100 MRSA isolates, 63 (63%) were resistant to gentamicin, erythromycin, clindamycin, and ciprofloxacin, however, all were sensitive to ceftaroline. Fifteen isolates (15%) were vancomycin intermediate resistant and were sensitive to ceftaroline as well. Conclusion: Ceftaroline was potent against MRSA, which was found to be non-susceptible to vancomycin, ciprofloxacin, erythromycin, clindamycin, and gentamicin and it may represent a successful treatment for MRSA infections.

3.Toxicity Profile and Pharmacokinetic Study of Antibiotic Mixtures, Gentamicin and Vancomycin, in rat plasma by Eco-friendly Liquid Chromatography coupled Tandem Mass Spectrometry/PMID 32940458; Chemical research in toxicology 2020 Sep; ?(?):/Name matches: amikacin gentamicin
Abstract:The global burden of bacterial infection and antimicrobial resistance increases the demand to associate more than one antibiotic to fight life-threatening bacteria. Therefore, there is a great necessity to develop simple and sensitive methods for routine analysis of clinical samples. Therapeutic drug monitoring, bioequivalence, and pharmacokinetic studies are essential to ensure drug efficiency and safety. Herein, therefore, the first ecofriendly liquid chromatography -tandem mass spectrometry (LC-MS/MS) method was developed and fully validated for simultaneous determination of a commonly combined antibiotic for methicillin-resistant Staphylococcus aureus (MRSA), vancomycin (VCM) and gentamicin (GTM), in rat plasma after parenteral administration. VCM and GTM were extracted from plasma sample using acetonitrile (ACN)/0.1% TFA-induced protein precipitation followed by the separation on an Agilent Eclipse Plus ODS (3 mm × 100 mm, 3.5 μm) column using water-enriched mobile phase consisting of water containing 0.1% THF/ACN (85:15, v/v%) at flow rates of 0.30 mL min-1. The mass spectrometry parameters were optimized, and multiple reaction monitoring (MRM) in positive ion mode of two transitions was utilized for quantification of precursor to product ion at m/z 725.5 → 144 and 100.1 for VCM as [M + 2H]2+, 478.3 → 322.2 and 156.9 for GTM, and 586.3 → 162.9 and 425.3 for amikacin (AMK) internal standard, as [M + H]+. The current method has been validated as per U.S. FDA bioanalytical guidelines in terms of linearity, accuracy, precision, selectivity, recovery, matrix effects, and stability. The method was linear in the range of 1-2000 ng mL-1 and 1-1000 ng mL-1 with detection limits (S/N of 3) of 0.18 and 0.09 ng mL-1 for VCM and GTM, respectively. The selectivity and high sensitivity allow the current method to succeed in the study of pharmacokinetic parameters and drug-drug interaction between VCM and GTM after single-dose administration. VCM increased plasma clearance and elimination rate constant of GTM when coadministered and GTM also too. The change of serum chemistry analysis and significant elevation of creatinine and BUN indicate an alteration in kidney function in group III in those given the combined antibiotics. Our finding illustrated the nephrotoxicity of the two drugs when associated. The ecofriendly, simplicity, and rapidity of the current study made it a promising method for high-throughput biomonitoring in clinical samples.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

Ren 化学品安全技术说明书			版本：1.0
按照GB/T16483、GB/T17519编制			修订日期：10.07.2019
			打印日期：19.02.2020
版权所有：范德（北京）生物科技有限责任公司			最初编制日期：25.05.2017
公司网站：WWW.BIO-FOUNT.COM			SDS编号：BIOFOUNT-SS0338
版权所有：BIOFOUNT BEIJING BIO TECH CO.,LTD			产品编号：SS0338
庆大霉素C1a,
说明书目录
第1部分	化学品及企业标识		第2部分	危险性概述
第3部分	成分/组成信息		第4部分	急救措施
第5部分	消防措施		第6部分	泄露应急处理
第7部分	操作处置与储存		第8部分	接触控制/个体防护
第9部分	理化性质		第10部分	稳定性和反应性
第11部分	毒理学信息		第12部分	生态学危害信息
第13部分	废弃处置		第14部分	运输信息
第15部分	法律法规信息		第16部分	其他补充信息
第1部分：化学品及企业标识
1.1 产品标识
产品名称：		庆大霉素C1a,
ENGLISH NAME：		Gentamicin,对照品
产品编号：		SS0338
品牌：		BIOFOUNT
化学文摘登记号(CAS NO.)：		1403-66-3
1.2 安全技术说明书提供者的详情
制造商或供应商名称：		BIOFOUNT BEIJING BIO-TECH CO.,LTD
制造地址：		59 KANGTAI AVENUE BINHAI NEW DISTRICT TIANJIN 300450 TIANJIN CHINA 范德(天津)生物科技有限责任公司天津市滨海新区康泰大道59号九州通绿谷健康产业园邮政编码：300450
电话号码：
1.3 应急咨询电话
紧急联系电话：
1.4 物质或混合物的推荐用途和限制用途
已确认的各用途：		仅用于科学研发，不作为药品、家庭或其它用途。
第2部分：危险性概述
2.1 GHS危险性类别
暂无数据
2.2 GHS 标签要素，包括防范说明
象形图
暂无数据
信号词
Danger
危险申明
H317 (55.42%) H334 (55.42%) H360 (44.58%)
警告申明
暂无数据
预防措施
暂无数据
事故响应
1.化学品使用过程中，当出现事故或者有紧急情况发生时，当事人应第一时间向应急小组负责人汇报后，由应急小组采取措施防止事态扩大。2.应急小组对受害人采取救护措施。
储存
暂无数据
废弃处置
暂无数据
2.3 物理和化学危险
暂无数据
2.4 健康危害
暂无数据
2.5 环境危害
暂无数据
2.6 其它危害物
暂无数据
第3部分：成分/组成信息
物质/混合物		暂无数据
3.1 物质
分子式		C60H123N15O21
分子量		477.6
化学文摘登记号(CAS NO.)		1403-66-3
EC-编号		暂无数据
根据相应法规，无需披露具体组份。
第4部分：急救措施
4.1 必要的急救措施描述
吸入
立即将患者移至空气新鲜处，发现呼吸困难时，必须立即采取吸氧处理，停止呼吸时采取人工呼吸。同时联系及时就医。
皮肤接触
立即脱去或者剪去污染的衣物，迅速用大量的流动清水冲10-20分钟甚至更长时间后，赴医院就医。
眼睛接触
立即用大量的流动清水冲10-20分钟后赴医院就医处理。
食入
误食化学物品后，应立即采取措施进行催吐。1.若误食化学品呈酸性，则可服用大量牛奶和水，促使食如折呕吐。2.若误食化学品呈碱性，则可服用大量牛奶、清水和醋，促使其呕吐，紧急处理后，应及时送至医院进行治疗（仅供参考）。食如者昏迷状态下禁止催吐，以免造成窒息。
4.2 最重要的症状和健康影响
最重要的已知症状及作用已在标签（参见章节2.2）和/或章节11中介绍
4.3 及时的医疗处理和所需的特殊处理的说明和指示
暂无数据
4.4 对医生的特别提示
暂无数据
第5部分：消防措施
5.1 灭火介质
灭火方法及灭火剂
采用泡沫灭火器、二氧化碳灭火器，避免造成二次污染发生。
5.2 源于此物质或混合物的特别的危害
暂无数据
5.3 灭火注意事项及保护措施
小规模着火需戴好口罩，防止有毒气体吸入。火灾发生时及时启动应急相应系统撤离至上风口处，并联系当地消防部门灭火。
第6部分：泄露应急处理
6.1 人员防护措施、防护装备和应急处置程序
1.泄露后首先启动应急相应系统2.泄露处理前，需穿戴好安全安全防护鞋、穿戴好安全防护手套（强酸性物质需穿戴防酸碱手套）、根据吸入危险性穿戴相应防护面罩。有关个人防护，请看第8部分。
6.2 环境保护措施
参照《范德生物化学废弃物处理方法》处理，防止对环境造成危害，处理后交由有资质的废弃物处理结构进行处理，以免造成环境污染。
6.3 泄漏化学品的收容、清除方法及所使用的处置材料
参照《范德生物化学品废弃物处理方法》对泄露的化学品进行处理，处理前需用化学品吸附岩棉对泄露区域进行围挡，形成“围堰”防止泄露扩大。
6.4 参考其他部分
丢弃处理请参阅第13节。
第7部分：操作处置与储存
7.1 安全操作的注意事项
使用过程请穿戴好口罩，手套等防护用品，避免与皮肤接触、吸入、误食危险。有关预防措施，请参见章节2.2。
7.2 安全储存的条件,包括任何不兼容性
暂时无法提供详细数据,尽可能避免与其他化合物混合存储，避光、通风处存储。
第8部分：接触控制/个体防护
8.1 控制参数
危害组成及职业接触限值
暂无数据
8.2 暴露控制
适当的技术控制
暂无数据
个体防护装备
眼面防护一般情况下穿戴安全防护眼镜即可，如有飞溅液体、粉末产生时，请佩戴防溅面罩进行防护。穿戴的防护用品需取得如：GB、NIOSH (美国) 或 EN 166(欧盟) 等相关认证。
皮肤保护手套脱去注意事项：手套在使用前必须进行检查，请使用正确的方法脱除手套(不接触手套外部表面)，避免身体任何皮肤部位接触到此产品。根据相关法律法规和实验室管理规范制度，手套使用过后，请将被污染的手套谨慎处理，工作后清洗并吹干双手。所选择的保护手套必须符合法规《劳动防护用品配备标准》、(EU)2016/425以及从此类法规衍生出来的EN 374标准规范。完全接触保护要求：手套材料：丁腈橡胶手套最小的层厚度：0.11 MM 手套溶剂渗透时间：480 分钟飞溅保护要求：材料：丁腈橡胶最小的层厚度 0.11 MM 溶剂渗透时间：480 分钟如果以溶剂形式应用或与其它物质混合应用，或在不同于《劳动防护用品配备标准》，EN 374规定的条件下应用，请与EC批准的手套的供应商联系。该条只是作为推荐性建议，如遇特殊情况，务必请熟悉该产品属性的专家，选取相关防护用品。此条建议不应该被认定为适应所有特殊条件防护，请根据所处工作条件请求专业工程师指导采取相应防护措施。
身体保护选择身体部分的防护措施，需要根据危险物质的类型、浓度、量以及特定的工作环境。身体部分防护设备、防护服的类型，必须根据使用者工作场所中的危险物质的浓度、数量进行选择。
呼吸系统防护一般情况下穿戴普通的医用口罩保护呼吸系统即可。有酸雾产生式活性炭类口罩起不到防护作用，如需对粉尘造成损害进行防护时，请采用N95型（US）或P1型（EN 143)类口罩或者防尘面具。特殊情况下使用自吸式呼吸器时，使用的呼吸器必须对呼吸器密闭性、空气供应系统、供气压进行测试，当然呼吸器需通过强制认证标准如：GB、NIOSH（US）、CEN（EU）。
环境暴露的控制
不要让产品进入下水道。
第9部分：理化特性
9.1 基本的理化特性的信息
外观与性状		形状：暂无数据
		颜色：暂无数据
气味		暂无数据
气味阈值		暂无数据
PH值		暂无数据
熔点/凝固点		暂无数据
初沸点和沸程		669.4±55.0 °C at 760 mmHg
闪点		358.6±31.5 °C
蒸发速率		暂无数据
易燃性(固体,气体)		暂无数据
高的/低的燃烧性或爆炸性限度		暂无数据
蒸气压		0.0±4.6 mmHg at 25°C
蒸气焓		112.6±6.0 kJ/mol
密度/相对密度		1.3±0.1 g/cm3
溶解度		暂无数据
正辛醇/水分配系数		Log Kow (KOWWIN v1.67 estimate) = -1.48
正辛醇空气分配系数		Log Kow used: -1.48 (KowWin est) Log Kaw used: -33.359 (HenryWin est) Log Koa (KOAWIN v1.10 estimate): 31.879 Log Koa (experimental database): None
自燃温度		暂无数据
分解温度		暂无数据
黏度		暂无数据
爆炸特性		暂无数据
氧化性		暂无数据
根据碎片估算水溶胶		Wat Sol (v1.01 est) = 1e+006 mg/L
亨利定律常数（25摄氏度）		Bond Method : 1.07E-035 atm-m3/mole Group Method: Incomplete Henrys LC [VP/WSol estimate using EPI values]: 1.154E-023 atm-m3
9.2 其他安全信息
暂无数据
第10部分：稳定性和反应性
10.1 稳定性
暂无数据
10.2 危险反应
暂无数据
10.3 应避免的条件
暂无数据
10.4 禁配物
强氧化剂
10.5 危险的分解产物
暂无数据
第11部分：毒理学信息
11.1 毒理学影响信息
毒性
暂无数据
皮肤腐蚀/刺激
暂无数据
严重眼睛损伤/眼刺激
暂无数据
呼吸或皮肤过敏
暂无数据
生殖细胞致突变性
暂无数据
致癌性
暂无数据
生殖毒性
暂无数据
特异性靶器官系统毒性（一次接触）
暂无数据
特异性靶器官系统毒性（反复接触）
暂无数据
吸入危害
暂无数据
附加说明
暂无数据
第12部分：生态学危害信息
12.1 生态毒性
暂无数据
12.2 持久性和降解性
暂无数据
12.3 快速生物降解的可能性
Biowin1 (Linear Model) : 0.0334 Biowin2 (Non-Linear Model) : 0.0000
12.4 专家调查生物降解结果
Biowin3 (Ultimate Survey Model): 2.3391 (weeks-months) Biowin4 (Primary Survey Model) : 3.4416 (days-weeks )
12.5 MITI生物降解的可能性
Biowin5 (MITI Linear Model) : 0.0202 Biowin6 (MITI Non-Linear Model): 0.0000
12.6 厌氧生物降解的可能性
Biowin7 (Anaerobic Linear Model): 0.0946
12.7 现成的生物降解性预测
NO
12.8 碳氢化合物生物降解
Structure incompatible with current estimation method!
12.9 对气溶胶的吸附
Vapor pressure (liquid/subcooled): 2.21E-013 Pa (1.66E-015 mm Hg) Log Koa (Koawin est ): 31.879 Kp (particle/gas partition coef. (m3/ug)): Mackay model : 1.36E+007 Octanol/air (Koa) model: 1.86E+019
12.10 羟基自由基反应
OVERALL OH Rate Constant = 498.6533 E-12 cm3/molecule-sec Half-Life = 0.021 Days (12-hr day; 1.5E6 OH/cm3) Half-Life = 15.444 Min
12.11 臭氧反应
No Ozone Reaction Estimation
12.12 空气中颗粒物吸附的分数（PHI）
1 (Junge,Mackay) Note: the sorbed fraction may be resistant to atmospheric oxidation
12.13 土壤吸附系数
Koc : 10 Log Koc: 1.000
12.14 碱/酸催化水解（25℃）
Rate constants can NOT be estimated for this structure!/
12.15 利用对数KOW估算生物累积量
Log BCF from regression-based method = 0.500 (BCF = 3.162) log Kow used: -1.48 (estimated)
12.16 废水处理中的去除
Total removal: 1.85 percent Total biodegradation: 0.09 percent Total sludge adsorption: 1.75 percent Total to Air: 0.00 percent (using 10000 hr Bio P,A,S)
12.17 三级逸度模型
Mass Amount Half-Life Emissions (percent) (hr) (kg/hr) Air 1.51e-019 0.515 1000 Water 46.4 900 1000 Soil 53.5 1.8e+003 1000 Sediment 0.0891 8.1e+003 0 Persistence Time: 973 hr
12.18 土壤中的迁移性
暂无数据
12.19 PBT和VPVB的结果评价
暂无数据
12.20 其他环境有害作用
暂无数据
第13部分：废弃处置
13.1 废物处理
方法产品
None
污染包装物
None
第14部分：运输信息
14.1 联合国编号 / UN NUMBER
欧洲陆运危规 / ER/RID：		None
国际海运危规 / IMDG：		None
国际空运危规 / IATA-DGR：		None
14.2 联合国运输名称 / UN PROPER SHIPPING NAME
欧洲陆运危规：		None
国际海运危规：		None
国际空运危规：		None
14.3 运输危险类别 / TRANSPORT HAZARD CLASS(ES)
欧洲陆运危规 / ER/RID：		None
国际海运危规 / IMDG：		None
国际空运危规 / IATA-DGR：		None
14.4 包裹组 / PACKAGING GROUP
欧洲陆运危规 / ER/RID ：		None
国际海运危规 / IM0DG：		None
国际空运危规 / IATA-DGR：		None
14.5 环境危害 / ENVIRONMENTAL HAZARDS
None
14.6 特殊防范措施 / SPECIAL PRECAUTIONS FOR USER
None
14.7 禁配物 / INCOMPATIBLE MATERIALS
None
第15部分：法律法规信息
15.1 专门对此物质或混合物的安全，健康和环境的规章/法规
适用法规
《中华人民共和国安全生产法》、《职业病防治法》、《化学化工实验室安全管理规范》
其它的规定
《生产安全事故报告和调查处理条例》、《职业病防治法》、《职业安全和卫生法》美国1970
第16部分：其他补充信息
其他信息版权所有：BIOFOUNT BEIJING BIO TECH CO.,LTD 公司。许可无限制纸张拷贝，仅限于内部使用。上述信息视为正确，但不包含所有的信息，仅作为指引使用。本文件中的信息是基于我们目前所知，就正确的安全提示来说适用于本品。该信息不代表对此产品性质的保证。BIOFOUNT公司及其附属公司对任何操作或者接触上述产品而引起的损害不负有任何责任。更多使用条款，参见发票或包装条的反面。更多销售条款及条件请参见HTTP://WWW.BIO-FOUNT.COM/或发票或装箱单的背面。欲悉详情，请联系：SALES@BIO-FOUNT.COM